Jaime Zorrilla Ortúzar

Dr. Jaime Zorrilla Ortúzar

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
DHDolores Herreros
Dolores Herreros
IPIsabel Pascual
Isabel Pascual
JPJosé Antonio Pascual
José Antonio Pascual
EDEmilio Del-Valle
Emilio Del-Valle
MPMaria Pascual
Maria Pascual
The feasibility and safety of stem cell-based therapy with expanded adipose-derived stem cells (ASCs) has been investigated in a phase I clinical trial. The present study was designed as a phase II multicenter, randomized controlled trial to further investigate the effectiveness and safety of ASCs in the treatment of complex perianal fistulas. Patients with complex perianal fistulas (cryptoglandular origin, n = 35; associated with Crohn's disease, n = 14) were randomly assigned to intralesional treatment with fibrin glue or fibrin glue plus 20 million ASCs. Fistula healing and quality of life (SF-12 questionnaire) were evaluated at eight weeks and one year. If healing was not seen at eight weeks, a second dose of fibrin glue or fibrin glue plus 40 million ASCs was administered. Fistula healing was observed in 17 (71 percent) of 24 patients who received ASCs in addition to fibrin glue compared with 4 (16 percent) of 25 patients who received fibrin glue alone (relative risk for healing, 4.43; confidence interval, 1.74-11.27); P < 0.001). The proportion of patients with healing was similar in Crohn's and non-Crohn's subgroups. ASCs were also more effective than fibrin glue alone in patients with a suprasphincteric fistulous tract (P = 0.001). Quality of life scores were higher in patients who received ASCs than in those who received fibrin glue alone. At one year follow-up, the recurrence rate in patients treated with ASCs was 17.6 percent. Both treatments were well tolerated. Administration of expanded ASCs (20 to 60 million cells) in combination with fibrin glue is an effective and safe treatment for complex perianal fistula and appears to achieve higher rates of healing than fibrin glue alone.

24 April 2020 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
VSVicente Simo
Vicente Simo
PTPatricia Tejedor
Patricia Tejedor
LJLuis Miguel Jimenez
Luis Miguel Jimenez
CHCristina Hernan
Cristina Hernan
JOJaime Zorrilla Ortúzar
Jaime Zorrilla Ortúzar
CPCarlos Pastor
Carlos Pastor

27 June 2018 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
ODOscar Díaz-Cambronero
Oscar Díaz-Cambronero
BLBlas Flor Lorente
Blas Flor Lorente
GMGuido Mazzinari
Guido Mazzinari
MMMaria Vila Montañes
Maria Vila Montañes
NGNuria García Gregorio
Nuria García Gregorio
David Cuesta-FrauDavid Cuesta-Frau
David Cuesta-Frau
1

1 June 2007 in Cirugía Española
Verified
Journal Article
Closed access
JSJuan María Sánchez-Tocino
Juan María Sánchez-Tocino
FTFernando Turégano-Fuentes
Fernando Turégano-Fuentes
DPDolores Pérez-Díaz
Dolores Pérez-Díaz
MSMercedes Sanz-Sánchez
Mercedes Sanz-Sánchez
JLJesús Lago-Oliver
Jesús Lago-Oliver
DMDarío Martínez-Baena
Darío Martínez-Baena

5 September 2013 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
FMFelipe Ángel Calvo Manuel
Felipe Ángel Calvo Manuel
CSClaudio V. Sole
Claudio V. Sole
JSJavier Serrano
Javier Serrano
MRMarcos Rodriguez
Marcos Rodriguez
FMFrancisco Álvarez Marcos
Francisco Álvarez Marcos
EVEmilio del Valle
Emilio del Valle

14 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
LOLuis Olmedilla
Luis Olmedilla
ODOscar Díaz-Cambronero
Oscar Díaz-Cambronero
GMGuido Mazzinari
Guido Mazzinari
JPJosé María Pérez Peña
José María Pérez Peña
JOJaime Zorrilla Ortúzar
Jaime Zorrilla Ortúzar
OIon behalf of the IPPColLapSe II investigators
on behalf of the IPPColLapSe II investigators
High intra-abdominal pressure (IAP) during laparoscopic surgery is associated with reduced splanchnic blood flow. It is uncertain whether a low IAP prevents this reduction. We assessed the effect of an individualized low-pneumoperitoneum-pressure strategy on liver perfusion. This was a single-center substudy of the multicenter ‘Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery versus Standard Therapy II study’ (IPPCollapse–II), a randomized clinical trial in which patients received an individualized low-pneumoperitoneum strategy (IPP) or a standard pneumoperitoneum strategy (SPP). Liver perfusion was indirectly assessed by the indocyanine green plasma disappearance rate (ICG–PDR) and the secondary endpoint was ICG retention rate after 15 min (R15) using pulse spectrophotometry. Multivariable beta regression was used to assess the association between group assignment and ICG–PDR and ICG–R15. All 29 patients from the participating center were included. Median IAP was 8 (25th–75th percentile: 8–10) versus 12 (12,12) mmHg, in IPP and SPP patients, respectively (p < 0.001). ICG–PDR was higher (OR 1.42, 95%-CI 1.10–1.82; p = 0.006) and PDR–R15 was lower in IPP patients compared with SPP patients (OR 0.46, 95%-CI 0.29–0.73; p = 0.001). During laparoscopic colorectal surgery, an individualized low pneumoperitoneum may prevent a reduction in liver perfusion.